Pharma — Marts 2024
-
Novartis: New SMART Study Data Continues To Support Zolgensma's Clinical Benefits In SMA https://www.proinvestor.com/investornyt/1126513/novartis-new-smart-study-data-continues-to-support-zolgensmas-clinical-benefits-in-sma
-
AstraZeneca's Datopotamab Deruxtecan Applications Validated In EU For Lung Cancer, Breast Cancer https://www.proinvestor.com/investornyt/1126526/astrazenecas-datopotamab-deruxtecan-applications-validated-in-eu-for-lung-cancer-breast-cancer
-
Lundbeck gør klar til fase 3-studie af MSA-middel efter opmuntrende data https://www.proinvestor.com/investornyt/1127205/lundbeck-gor-klar-til-fase-3-studie-af-msa-middel-efter-opmuntrende-data
-
Eli Lillys alzheimerskandidat står over for yderligere
forsinkelsehttps://www.proinvestor.com/investornyt/1129011/eli-lillys-alzheimerskandidat-star-over-for-yderligere-forsinkelse -
Why Eli Lilly Stock Flopped on Friday https://www.proinvestor.com/investornyt/1129450/why-eli-lilly-stock-flopped-on-friday
-
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates https://www.proinvestor.com/investornyt/1129459/pharma-stock-roundup-nvos-new-obesity-pill-data-rhhby-azns-pipeline-updates
-
Lundbeck går videre med studie af migrænemiddel https://www.proinvestor.com/investornyt/1132204/lundbeck-gar-videre-med-studie-af-migraenemiddel
-
Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It. https://www.proinvestor.com/investornyt/1132739/johnson-amp-johnson-stock-is-great-heres-why-you-shouldnt-buy-it
-
Sydbank ser pænt potentiale i Lundbecks to varmeste interne lægemiddelkandidater https://www.proinvestor.com/investornyt/1133092/sydbank-ser-paent-potentiale-i-lundbecks-to-varmeste-interne-laegemiddelkandidater
-
Tak for indsatsen i Bava chatten, The Note! Desværre er en lille hård klike gået helt i selvsving derinde i kritik af alt og alle der har med Bava at gøre. Så meget at ingen andre gider skrive derinde, så længe de folder sig ud. Vi snax ved derinde senere på året/næste år, efterhånden som øget omsætning/indtjening sætter sig igennem
-
AstraZeneca Announces FDA Approval For Ultomiris - Quick Facts https://www.proinvestor.com/investornyt/1135990/astrazeneca-announces-fda-approval-for-ultomiris-quick-facts
-
Ultimovacs - Jeg var investor i Ultimovacs før INITIUM studiet kom ud med resultater. Jeg valgte ikke at sælge mine aktier fordi jeg syntes studie-resultatet ikke entydigt viser at vaccinen UV1 ikke virker. Jeg mener der har været en overreaktion. Jeg har derfor haft meget travlt med at tale med fagfolk om dette. Jeg har besluttet at invester yderligere de seneste dage. Jeg skal opdatere med et debat-indlæg senere i påske-ugen.
-
FDA Approves Merck's Winrevair For Treatment Of Pulmonary Arterial Hypertension In Adults https://www.proinvestor.com/investornyt/1137074/fda-approves-mercks-winrevair-for-treatment-of-pulmonary-arterial-hypertension-in-adults
-
Lundbeck får godkendt langtidsvirkende middel til behandling af skizofreni i EU https://www.proinvestor.com/investornyt/1137101/lundbeck-far-godkendt-langtidsvirkende-middel-til-behandling-af-skizofreni-i-eu
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind